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1322 The Journal of Thoracic and CardObjectives: In studying cardiac surgical patients undergoing atrial fibrillation abla-
tion with bipolar radiofrequency, we sought to (1) quantify the time-related prev-
alence of atrial fibrillation postoperatively and identify its risk factors and (2)
determine time-related ablation failure and its risk factors.
Methods: From November 2001 to January 2004, 513 patients underwent atrial
fibrillation ablation (bipolar radiofrequency alone or with cryothermy) and other
cardiac operations. Rhythm documented on 3495 postoperative electrocardiograms
was used to estimate the prevalence of and risk factors for atrial fibrillation across
time. Ablation failure was defined as occurrence of atrial fibrillation any time
beyond 6 months after operation.
Results: Prevalence of postoperative atrial fibrillation peaked at about 1 month,
decreased to 13% at 6 months, and gradually increased thereafter. Risk factors
associated with increased prevalence varied by time period and included older age
(P  .004) for early occurrence, lesion set in permanent atrial fibrillation (P  .02)
for late occurrence, and larger left atrial diameter (P  .02) and permanent atrial
fibrillation (P  .0001) for occurrence across the entire time span. Freedom from
ablation failure was 72% at 12 months. Risk factors for ablation failure included
lesion set in permanent atrial fibrillation (P  .001), longer duration of atrial
fibrillation (P  .01), and larger left atrial diameter (P  .03).
Conclusions: Bipolar radiofrequency enables extension of ablation to most cardiac
surgical patients with atrial fibrillation. Recurrence is influenced by the type and
duration of atrial fibrillation, choice of lesion set in permanent atrial fibrillation, and
left atrial size. Early operation, careful choice of lesion set, and left atrial reduction
might enhance results.
Atrial fibrillation (AF) is common in patients presenting for cardiac surgeryand, if left untreated, is associated with reduced survival and increased riskof stroke. Successful intraoperative ablation of AF improves outcomes,1-3
but until recently, surgeons were unlikely to combine ablation and other cardiac
operations. This is because although the Cox maze III procedure eliminates AF in
70% to 90% of patients, it is complex and increases operative time.3-5
Recently, there has been great interest in direct surgical ablation of AF, fueled by
technologic advances and demonstration that the pulmonary veins and left atrium
are the primary sites of drivers of AF.6-12 Ablation technologies, such as bipolar
radiofrequency (RF), enable surgeons to isolate the pulmonary veins and create
linear left atrial lesions rapidly and safely.6-11 However, results of these new
procedures require scrutiny. The objectives of this study of cardiac surgical patients
undergoing AF ablation with bipolar RF were to (1) quantify the time-related
prevalence of AF after operation and identify its risk factors and (2) determine
time-related ablation failure and its risk factors.
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Patients
From November 2001 to January 2004, 513 patients underwent AF
ablation with bipolar RF at The Cleveland Clinic Foundation. This
represents 25% of the 2079 patients with preoperative AF under-
going cardiac surgery during this time frame and 67% of the 769
patients who had some form of AF ablation. Patients were iden-
tified, and preoperative, operative, and postoperative variables
were retrieved from the Cardiovascular Information Registry,
which has been approved for research by the institutional review
board. Mean patient age was 67  12 years (Table 1). The most
common indication for operation was mitral valve disease (69%).
AF was classified as paroxysmal (27%), persistent (14%), or
permanent (56%)13; 2.1% of patients had atrial flutter as their
primary arrhythmia. Median duration of preoperative AF was 24
months (range, 1-612 months). Mean left atrial diameter was 5.1
0.9 cm. Preoperative treatment of AF consisted of antiarrhythmic
medications (n  147 [29%]), warfarin (n  215 [42%]), and
electrical cardioversion (n  69 [13%]). Preoperative thromboem-
bolic events included transient ischemic attack (10%), stroke (9%),
and other systemic embolism (2%).
AF Ablation
Bipolar RF. All patients underwent AF ablation with the Atri-
cure (West Chester, Ohio) bipolar RF system. In this system,
electrodes reside in the jaws of an atraumatic clamp. Energy
delivery is continued until tissue conductance between electrodes
decreases and reaches a steady state for 2 seconds, indicating
transmural conduction block.8,9
Lesion sets. Ablation was generally performed after cardiac
arrest but before the principal operative procedure. Lesion sets
varied over time and were performed at the discretion of the
TABLE 1. continued
Characteristic n* No. %
Preoperative thrombolic events 513
Syncope 49 9.6
Transient ischemic attack 49 9.6
CVA 48 9.4
Embolus 9 1.8
Intraoperative support
Aortic clamp time (min) 504 87 32
CPB time (min) 512 113 39
Procedure 513
Mitral valve repair 227 44
Mitral valve replacement 127 25
Aortic valve replacement 164 32
Tricuspid valve repair 133 26
CABG 195 38
NYHA, New York Heart Association; LAD, left anterior descending coro-
nary artery; LV, left ventricle; LA, left atrium; BUN, blood urea nitrogen;
CVA, cerebrovascular accident; CPB, cardiopulmonary bypass; CABG,
coronary artery bypass grafting. *Data available. †50%. ‡Percent of
patients undergoing mitral valve surgery. §15th, 50th (median), and 85th
percentiles.TABLE 1. Patient characteristics
Characteristic n* No. %
Demographic 513
Male 298 58
Age (y), mean  SD 67 12
Cardiac
NYHA functional class 513
I 93 18
II 293 57
III 111 22
IV 16 3.1
Emergency operation 513 4 0.78
Left main disease† 493 34 6.9
LAD disease† 493 165 33
Circumflex disease† 493 133 27
Right coronary disease† 489 144 29
Previous cardiac operation 513
0 426 83
1 76 15
2 10 2.0
3 1 0.19
History of myocardial infarction 513 141 27
Mitral valve disease cause 513 354 69
Degenerative‡ 211 60
Rheumatic‡ 76 21
Ischemic‡ 36 10
Endocarditis‡ 2 0.56
Functional‡ 16 4.5
Radiation‡ 2 0.6
Prosthetic valve dysfunction‡ 10 2.8
Unspecified‡ 1 0.3
Mitral regurgitation grade 512
0 67 13
1 70 14
2 67 13
3 108 21
4 200 39
Atrial fibrillation type 513
Permanent 289 56
Persistent 74 14
Paroxysmal 139 27
Flutter 11 2.1
Duration of atrial fibrillation (mo) 512 3, 24, 108§
LV end-diastolic diameter (cm) 444 5.1 0.98
LV end-systolic diameter (cm) 442 3.5 1.1
LA diameter (cm) 427 5.12 0.90
Fractional shortening 442 0.32 0.12
Ejection fraction (%) 442 58 18
Estimated wall stress 442 0.49 0.17
Noncardiac
Hypertension 510 327 64
BUN (mg · dL1) 508 22  11
Bilirubin (mg · dL1) 480 0.5, 0.8, 1.4§surgeon in a nonrandomized fashion (see Electronic Appendix
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these were termed lesion sets 1, 2, 3, and 4 (Figure 1). In all
patients, pulmonary veins were isolated with the bipolar RF clamp.
Left atrial connecting lesions (lesion sets 2, 3, and 4) were
created with the bipolar clamp by opening the left atrium and
placing one jaw on the endocardium and one on the epicardium.
The lesion connecting the left pulmonary veins to the mitral
annulus (left atrial isthmus, lesion sets 3 and 4) was created by
using cryothermy (Cooper Surgical, Shelton, Conn). The left atrial
appendage was excluded or excised in all patients. Some patients
in each group had connecting lesions from the left atrial appendage
to the left pulmonary veins. One hundred seventy-five (34%)
patients received a cryothermy lesion on the right atrial isthmus.
There were differences between patients receiving different
lesion sets. Compared with those receiving lesion set 1, patients
receiving lesion sets 2, 3, and 4 were more likely to have a mitral
valve procedure; in addition, those receiving lesion sets 3 and 4
were less likely to have paroxysmal AF. Compared with patients
receiving lesion set 1, patients with permanent AF receiving lesion
sets 2, 3, and 4 were more likely to have mitral valve disease and
left atrial enlargement and less likely to have coronary artery
disease (see Electronic Appendixes 1-4).
Follow-up
Postoperative electrocardiograms (ECGs) were used to assess AF.
ECGs were performed routinely before discharge and at the dis-
cretion of referring physicians during follow-up. Recommended
ECG follow-up intervals were 1 month, 3 months, 6 months, 1
year, and annually thereafter. A total of 3495 postoperative ECGs
were retrieved. Every patient had at least one record available for
analysis (range, 1 day to 25 months). One hundred ninety-five
Figure 1. Schematic representation of left atrial lesion sets cre-
ated with bipolar RF. White ovals represent mitral valve, sets of
4 black ovals represent pulmonary veins, and dashed lines rep-
resent sites of ablation. All ablation lesions are created with
bipolar RF, except in lesion sets 3 and 4, in which the lesion
connecting the left pulmonary vein lesion to the mitral valve
annulus is created with cryothermy.patients had an ECG 6 months or more after operation (Figure 2
1324 The Journal of Thoracic and Cardiovascular Surgery ● Junand see Electronic Appendix 5, available at www.mosby.com/
jtcvs). For purposes of analysis, any one of the following 3
rhythms was considered as postoperative AF: AF, atrial flutter, or
a paced rhythm with underlying AF or atrial flutter.
Clinical follow-up for survival, morbid events, and medication
history was obtained by using patient visit and systematic tele-
phone or mailed questionnaires at 3, 6, and 12 months. Median
clinical follow-up was 7 months, with a total of 317 patient-years
available for analysis. Use of class I and III antiarrhythmic drugs
and warfarin was recorded at each follow-up. Patients were ques-
tioned concerning recurrence of AF; however, only those episodes
identified by means of ECG were entered into the analyses.
Analysis and Depiction of Data
Prevalence of and risk factors for AF. Because there is no
practical method for continuous heart rhythm assessment, a novel
statistical technique was developed to depict the prevalence of AF
versus time on the basis of discrete ECG recordings. We attempted
to solve multiple challenges simultaneously: repeated ECG record-
ings for each patient (repeated measures), variable times of record-
ing, censoring by death, and a complex temporal pattern of AF
prevalence that likely represented the variable effect of different
modulating factors across time. The analytic approach taken was
temporal decomposition, using several simple additive compo-
nents (early, constant, and late in this instance) into which separate
streams of modulating variables were incorporated for simulta-
neous analysis. The mathematic models used were derived from
those previously used over the last 20 years for decomposition of
time-to-event data.14 Longitudinal binary logistic regression anal-
ysis for repeated measurements (PROC NLMIXED, SAS, Inc,
Cary, NC) was used to resolve the number of time components and
to estimate the shaping parameters of each.
Multivariable analysis was performed in the odds domain to
identify risk factors for each component (see Electronic Appendix 6,
available at www.mosby.com/jtcvs). Because of the limited ability of
Figure 2. Number of patients with ECG follow-up available at and
beyond various time points and number of ECGs available for
analysis at and beyond these same time points.PROC NLMIXED to explore multivariable relations, we screened
e 2005
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(PROC LOGISTIC, SAS) with a liberal retention criterion (P .15).
Candidate risk factors identified were entered at once into PROC
NLMIXED and then eliminated one by one until all variables remain-
ing had a P value of .1 or less.
Ablation failure and risk factors. Ablation failure was defined
as any occurrence of AF or atrial flutter 6 months or more after
ablation. Therefore, to be at risk of ablation failure, patients had to
have an ECG obtained in this timeframe. Patients were considered
to have ablation failure even if late AF was transient. Data were
considered interval censored, with the event assumed to occur
between the time of an ECG showing AF and the immediately
preceding ECG not showing AF.
To identify risk factors for ablation failure,14 a parametric
model was used to resolve a number of instantaneous risks of
the interval-censored event (hazard function) and to estimate
shaping parameters. (For additional details, see http://www.
clevelandclinic.org/heartcenter/hazard.) Variable selection was by
bootstrap bagging15,16 using a retention criterion of P less than .05
and considering variables appearing in 50% or more models as
reliably significant at this level.
Presentation
Predicted percentages of prevalence of AF and freedom-from-
event curves are accompanied by asymmetric 68% confidence
limits (CLs) comparable to 1 SE.
Results
In Hospital
There were no ablation device–related complications. Hos-
pital morbidity included stroke in 8 (2%) patients, transient
ischemic attack in 4 (1%), and reoperation for bleeding in
25 (5%). Strokes were judged to be related to the patient’s
underlying disease (atherosclerosis or calcified valvular
heart disease requiring extensive debridement). There were
Figure 3. Temporal pattern of AF after ablation on the basis of
postoperative ECGs. The solid line represents point estimates
enclosed within 68% bootstrap CLs.10 hospital deaths (2%; CL, 1.3%-2.8%). 
The Journal of ThoracicHeart Rhythm
Prevalence of AF and its risk factors. A curve demon-
strating the time-related predicted prevalence of AF or atrial
flutter after operation is depicted in Figure 3. Early preva-
lence of AF peaked at 38% (CL, 35%-41%) at 2 weeks. By
6 months, the prevalence decreased to 13% (CL, 12%-15%),
gradually increasing thereafter to 16% (CL, 13%-19%) at 1
year. At 6 months, 26% of patients were taking antiarrhyth-
mic medications (see Figure E2), and 50% were taking
warfarin (see Figure E3).
Temporal decomposition of AF prevalence yielded 3
time phases (see Figure E4), and multivariable analysis
identified different factors modulating each (Table 2). Be-
cause the number of ECGs collected for patients receiving
lesion set 4 was low after 6 months, lesion sets 3 and 4 were
combined as one set for all analyses.
Preoperative permanent AF (Figure 4, A) and larger left
atrial diameter (see Figure E5) were associated with in-
creased prevalence of AF. All lesion sets achieved similar
results with paroxysmal AF (Figure 4, C), but lesion set 2
was associated with increased prevalence of AF in patients
with permanent AF (Figure 4, C).
Ablation failure. One hundred ninety-five patients had
ECGs obtained 6 or more months after ablation and were
therefore at risk for ablation failure (see the “Materials and
Methods” section). Ablation failure occurred in 53 patients;
mode of failure was AF in 41 and atrial flutter in 12.
Freedoms from ablation failure were 72% at 12 months and
TABLE 2. Incremental risk factors for higher prevalence of
atrial fibrillation
Risk factor Estimate  SE P value
Overall
Preoperative permanent AF vs
paroxysmal
0.89 0.20 .0001
Preoperative persistent AF vs
paroxysmal
0.080 0.27 .8
Greater ventricular wall stress* 0.67 0.16 .0001
Larger left atrial diameter† 1.2  0.51 .02
Thinner septum‡ 1.1 0.57 .06
Early phase
Older age§ 1.5  0.52 .004
Greater aortic valve regurgitation 0.21 0.082 .01
Lesion set 2 vs 1 0.46 0.27 .09
Lesion sets 3 or 4 vs 1 0.19 0.23 .4
Constant phase
None
Late phase
Lesion set 2 and permanent AF 0.54 0.23 .02
AF, Atrial fibrillation. *(1/relative wall thickness), inverse transformation.
†(5/left atrial diameter), inverse transformation. ‡(1/septal thickness), in-
verse transformation. §(70/age), inverse transformation.66% at 18 months (Figure 5). Risk factors for ablation
and Cardiovascular Surgery ● Volume 129, Number 6 1325
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CDfailure included longer duration of preoperative AF, larger
left atrial diameter, and use of lesion set 2 in patients with
permanent AF (Table 3 and see Figure E6).
Discussion
Key Findings
This report documents early results with application of
bipolar RF to facilitate AF ablation in cardiac surgical
patients. Key findings are that (1) the prevalence of AF
peaks early after surgical intervention and then decreases
to 16% at 1 year, (2) freedom from ablation failure is
72% at 12 months, and (3) recurrence of AF is influenced
by the type and duration of AF, the choice of lesion set
in permanent AF, and left atrial size.
AF in Cardiac Surgical Patients
The rationale for restoring sinus rhythm in patients present-
ing for cardiac surgery includes (1) improving survival, (2)
Figure 5. Freedom from ablation failure. The solid line represents
parametric estimate enclosed within dashed 68% CLs. Numbers
in parentheses represent patients remaining at risk. The horizon-
tal scale begins at 6 months postoperatively because patients are
not at risk for ablation failure until that time.
TABLE 3. Risk factors for ablation failure
Risk factor Estimate  SE P value R (%)*
Lesion set 2 and permanent AF 1.1 0.33 .001 92
Longer duration of
preoperative AF†
0.29 0.12 .01 70
Larger left atrial diameter‡ 2.1  0.97 .03 49
Greater wall stress§ 1.3 0.62 .03 43
AF, Atrial fibrillation. *Reliability: percentage of occurrences in bootstrap
models. †Ln(duration of AF  1), logarithmic transformation. ‡(5/left atrial
diameter), inverse transformation. §(Relative wall thickness)2, squaredFigure 4. Nomograms from the multivariable equation (Table 2)
demonstrating effects of factors on prevalence of AF. A, Type of
AF. B, Lesion set in paroxysmal AF. There is no difference be-
tween lesions sets. C, Lesion set in permanent AF. Note that 1
refers to both lesion set 1 and miscellaneous additional lesions,
generally to the left atrial appendage. Results with lesion set 2
are inferior.transformation.
e 2005
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eliminating need for anticoagulation, (4) reducing symp-
toms associated with tachycardia, and (5) improving cardiac
output.1-3 Because most of these patients do not revert to
sinus rhythm with treatment of their primary cardiac lesion
(with the possible exception of AF of short duration), we
took an aggressive approach to ablation.17
Although the Cox maze III procedure restores sinus
rhythm or an atrioventricular paced rhythm in 75% to 95%
of patients undergoing concomitant cardiac surgery,1-5 it
has not been widely performed. Recently, there has been
great interest in treating AF surgically, which is attributable
to increased understanding of its pathogenesis and develop-
ment of new ablation technologies. In most patients, triggers
and substrates for AF are located in the left atrium and
pulmonary veins,12 and therefore ablation is now focused on
these areas. Alternative energy sources enable rapid creation
of lines of conduction block without the laborious cutting
and sewing of the Cox maze III procedure. Reported abla-
tion success ranges from 60% to 95% using a variety of
different energy sources and lesion sets in various types of
patients.6,7,10,11 However, there are few data identifying
patient- and procedure-related risk factors for ablation fail-
ure, and no valid statistical technique to assess results.7
Prevalence of AF, Ablation Failure, and Risk Factors
In the current study, bipolar RF was the predominant mo-
dality used to create left atrial lesions; cryothermy was used
to create lesions on the right and left atrial isthmuses in
some patients. Four basic left atrial lesion sets were used.
This variability in lesion sets, coupled with varying patient
characteristics and types and durations of AF, facilitated
identification of risk factors for return of AF and ablation
failure.
Risk factors for AF prevalence and ablation failure were
both patient and procedure related. Longer duration of AF,
permanent AF, and larger left atrial diameter increased
either the prevalence of AF, the risk of ablation failure, or
both. In fact, these characteristics tended to occur together
in the same patients. Others have demonstrated increased
risk of ablation failure when these factors were present.18-22
These findings suggest that it is unlikely that “one size fits
all” in ablating AF23; rather, a tailored approach is indi-
cated.
Procedural risk factors were related to choice of lesion
set. In patients with paroxysmal and persistent AF, all lesion
sets produced equivalent results. Each lesion set included
pulmonary vein isolation, suggesting that drivers of AF in
these patients might reside in the pulmonary veins. In con-
trast, choice of lesion set affected results in patients with
permanent AF. Those who received lesion sets 2, 3, and 4
tended to have mitral valve disease and left atrial enlarge-
ment (see Electronic Appendix 4 available at www.mosby.
The Journal of Thoraciccom/jtcvs). Lesion set 2, which does not include a lesion to
the mitral annulus, produced inferior results in these patients
compared with lesion sets 3 and 4. It has been suggested that
failure to ablate the left atrial isthmus jeopardizes suc-
cess.24,25 Our results support this concept in patients with
mitral valve disease. As in previous reports, addition of
right atrial lesions (eg, isthmus lesions) did not affect
results.26
Others have reported that lesion set affects results. Gay-
nor and colleagues27 found that the Cox maze III procedure
was more effective than the Cox maze I and II. Data from
catheter-based procedures in patients with paroxysmal AF
suggest that the more left atrial area isolated, the better the
freedom from AF.28-30
Limitations
This series contains early follow-up of a large cohort of pa-
tients undergoing intraoperative RF ablation with or without
cryothermy. ECGs used for analysis were obtained routinely in
the hospital but opportunistically after hospital discharge. Al-
though only 195 patients had ECGs beyond 6 months after
operation, there are a sufficient number for analysis. Patients
having late ECGs might be selected because they had symp-
tomatic AF, leading to overestimation of the prevalence of AF
and ablation failure. Alternatively, asymptomatic AF episodes
without ECG verification might have been missed, leading to
underestimation of events.31 Although periodic Holter moni-
toring and event recorders would have provided more data for
analysis, these methodologies might still fail to capture all AF
episodes. Limitations in the ability to document heart rhythm
continuously over time led us to develop novel statistical
methods that we believe provide accurate estimates of AF
prevalence. Although not perfect, this method represents an
important improvement over analyses relying on rhythm at last
follow-up or patient self-reporting.
Results of AF ablation were assessed and presented in 2
related but different fashions. We estimated the prevalence
of AF to depict the predicted prevalence of AF in the
population at any given time after ablation. In such a de-
piction, a given patient might have AF on one ECG and
sinus rhythm on the next, unlike in a time-to-event analysis.
We also estimated freedom from ablation failure, with ab-
lation failure defined as any recurrence of AF beyond 6
months after operation. Although this definition is stringent,
it is appropriate.
The analyses of prevalence of AF and ablation failure do
not take into account antiarrhythmic medications that pa-
tients might have been taking. The prevalence of antiar-
rhythmic medication use is depicted separately. Although we
recommend discontinuing antiarrhythmic agents 3 months af-
ter ablation, continued use is at the discretion of referring
cardiologists, which hampered our ability to report the preva-
lence of AF and freedom from ablation failure off medications.
and Cardiovascular Surgery ● Volume 129, Number 6 1327
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methods; it is therefore possible that operator error or other
factors might have resulted in some patients receiving in-
complete lesions, which might have contributed to ablation
failures.
Clinical Inferences
AF is common early but is transient after intraoperative
ablation. Early operation after the development of AF and
left atrial size reduction in those with enlarged left atria
might improve results. In patients with paroxysmal and
persistent AF, simple pulmonary vein isolation might be
adequate. In patients with permanent AF, we recommend
the left atrial lesion set of the Cox maze III procedure. A
prospective randomized clinical trial with longer follow-up
is necessary to test these strategies.
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Discussion
Dr Donald B. Doty (Salt Lake City, Utah). Dr Gillinov and his
associates have provided us with information on a large series of
patients, 513, having ablation procedures with bipolar RF for the
treatment of AF during slightly more than a 2-year period. It is a
retrospective study and is subject to all of the problems associated
e 2005
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CDwith such studies. One, there was no protocol or agreement as to
the lesion pattern in these patients. Choice was by surgeon discre-
tion, and the lesion pattern changed and evolved over time. The
patients were classified according to established American Heart
Association and American College of Cardiology criteria: parox-
ysmal, meaning easily or spontaneously converted to normal sinus
rhythm; persistent, probably can be converted; and permanent,
cannot be converted. But the lesion pattern choice was apparently
not consistently applied by category of patient.
The title of the article implies that bipolar RF energy was the
energy used to create left atrial ablation lesions, but the data show
that patients having lesion patterns 3 and 4 had the left atrial
isthmus lesion created by means of cryothermia and that one third
of the patients had right atrial inferior isthmus ablation lesions
created by means of cryothermia, presumably to prevent postop-
erative atrial flutter.
Data have been analyzed by using complex statistical methods
in an attempt to compensate for events occurring over time and in
which they used analysis of ECGs obtained nearly randomly in the
postoperative period. Terms such as longitudinal binary logistic
regression analysis and bootstrap bagging are used. Now Gene
Blackstone has explained this to me on frequent occasions, making
nearly perfect logical sense, and I accept these methods knowing
Gene Blackstone is correct, although I confess I really do not
understand them very well, and I am not even going to ask Marc
to try to explain them to us.
Dr Gillinov. But I am ready to explain them.
Dr Doty. Well, you do not have to. We accept them. And I
think the authors have done a very good job of making some
sense out of some difficult data, nearly 3500 ECGs. Let me give
you what my interpretation of these data is based on reading the
article and hearing what is presented, which quite accurately
matches the article. Except for the connecting lesion, lesion
patterns 1 and 2 are the same. These are patients who had in
common pulmonary vein isolation lesions, and they worked
well with the paroxysmal or persistent types of AF, in which
one would expect trigger points in the pulmonary veins to
initiate the arrhythmia. Lesion pattern 2 added the connecting
lesion, but this was not enough when it came to permanent
forms, and it has biased the data because the patients who had
lesion pattern 2 were heavily weighed with patients with mitral
valve disease, whereas the patients with lesion pattern 1 were
not, and therefore one would expect the data to come out that
way because the substrate for patients receiving lesion pattern 2
implies a much more complex pathogenesis of the AF than
trigger points in the left pulmonary veins.
Now lesion patterns 3 and 4 are also the same, having in
common pulmonary vein isolation and left atrial isthmus le-
sions, except that lesion pattern 4 has a double connecting
lesion, which, by the way, leads to a portion of the left atrial
posterior wall isolated from any electrical depolarization. And
this appears to be a more effective lesion pattern when the left
atrium is abnormal, such as in mitral valve disease. We do not
know from the data, and we have not heard anything presented,
what the effect of right atrial isthmus lesions, which were done
by means of cryothermia in about one third of these patients,
might be, and I would say that the conclusion of the authors,
proposed effect of left atrial reduction, is purely speculative
The Journal of Thoracicbecause there are no data in this presentation or the article on
which you can base that conclusion.
The first question is as follows: What is the added cost of
using 2 energy sources for this operation? Second, what is the
role of the right atrial isthmus ablation in the treatment of AF?
Three, should pulmonary vein isolation lesions be restricted to
patients having paroxysmal forms or perhaps persistent forms
of AF? And finally, what is the currently recommended lesion
pattern for permanent forms of AF?
Dr Gillinov. Thank you, Dr Doty, for all of your comments.
I think the preamble to your questions hits on something that
can be used as the strength of this presentation. It is incredibly
heterogeneous. There were 10 surgeons handling many differ-
ent types of patients with different lesion sets in different
approaches. At first glance that might produce just chaos, but on
the other hand, if you have enough patients and enough follow-
up, it allows you to discern patterns that relate to both the sort
of patients and the lesions created, and you can get the begin-
nings of some answers, and therefore the heterogeneity was
useful.
Regarding the cost of the 2 energy sources? Well, it is higher
than we would like, but we used the older reusable cryo system,
so that is a sunk cost from 15 years ago. It does not cost us
anything additional to use the Cooper Surgical or Frigitronics
system once we have already purchased it, and therefore we are
paying for only one disposable ablation unit per case. There are
people who create the isthmus lesion with RF. We have not
because of fear of injury to the circumflex artery, although I am
not sure that has been reported.
What about the right atrial isthmus lesion? We analyzed that to
determine whether its presence or absence is a risk factor for
failure. In our experience the answer is that no, it has no effect, and
therefore we create one now only in someone who has a history of
flutter.
Should pulmonary vein isolation be restricted to patients
with paroxysmal AF? Not entirely. Pulmonary vein isolation is
now our lesion set of choice with excision of the appendage in
the paroxysmal patient. However, in patients who are very ill
and who undergo a complex operation in which we do not want
to spend even the additional 10 minutes to open the atrium and
create connecting lesions, we will just do the pulmonary veins,
and about 40% or 50% of those might have some success. On
the other hand, if a patient has permanent AF and there is no
specific contraindication or difficulty to opening the atrium and
making connecting lesions, then our lesion set of choice in the
left atrium looks like a maze procedure.
Dr Vaughn Starnes (Los Angeles, Calif). It is not only a very
heterogeneous group of surgeons but also a heterogeneous popu-
lation of patients.
My question pertains to the mitral valve repair itself. Did the
repair and durability of that repair affect in any way the results
of your AF; that is, if you had some residual mitral regurgitation
or regurgitation developed, did it affect your outcome?
Dr Gillinov. I do not know whether recurrent mitral regurgitation
influences the results; it very well might. Because recurrent mitral
regurgitation and return of AF are both time-related outcomes of the
surgical procedure, analysis of their relationship is statistically chal-
lenging.
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Electronic Appendix 1. Patient characteristics according
Characteristic
1, n  194 (38%),
No. (%)
2, n
Demographic
Male 122 (63)
Cardiac comorbidity
NYHA functional class
I 30 (15)
II 106 (55)
III 50 (26)
IV 8 (4)
Emergency operation 4 (2)
Left main disease* 21 (11)
LAD disease* 82 (45)
Circumflex disease* 65 (35)
Right coronary disease* 75 (41)
Previous cardiac operation
0 160 (82)
1 28 (14)
2 6 (3)
3 0 (0)
Previous myocardial infarction 74 (38)
Mitral valve disease cause 90 (46)
Degenerative† 44 (49)
Rheumatic† 19 (21)
Ischemic† 17 (19)
Endocarditis† 0 (0)
Functional† 4 (4)
Radiation† 1 (1)
Prosthetic valve dysfunction† 5 (6)
Unspecified† 0 (0)
Mitral regurgitation grade
0 38 (20)
1 38 (20)
2 33 (17)
3 31 (16)
4 53 (27)
Atrial fibrillation type
Permanent 101 (52)
Persistent 25 (13)
Paroxysmal 65 (34)
Flutter 3 (1.6)
Noncardiac comorbidity
Hypertension 131 (68)
Preoperative thromboembolic event
Syncope 22 (11)
Transient ischemic attack 20 (10)
Cerebrovascular accident 24 (12)
Embolus 3 (1.6)
Procedure
Mitral valve repair 54 (28)
Mitral valve replacement 36 (19)
Aortic valve replacement 76 (39)
Tricuspid valve repair 50 (26)
Isolated CABG 31 (16)to lesion set: categoric variables
Lesion set
P value
 96 (19%),
No. (%)
3/4, n  183 (36%),
No. (%)
Other, n  40 (8%),
No. (%)
54 (56) 94 (51) 28 (70) .05
.4
18 (19) 38 (21) 7 (18)
51 (53) 109 (60) 27 (68)
23 (24) 32 (17) 6 (15)
4 (4) 4 (2) 0 (0)
0 (0) 0 (0) 0 (0) .08
7 (7) 4 (2) 2 (5) .007
30 (32) 38 (21) 15 (39) .0001
23 (24) 34 (19) 11 (29) .006
25 (27) 34 (19) 10 (26) .0001
.5
78 (81) 156 (85) 32 (80)
16 (17) 24 (13) 8 (20)
1 (1) 3 (1.6) 0 (0)
1 (1) 0 (0) 0 (0)
22 (23) 32 (17) 13 (32) .0001
74 (77) 152 (83) 38 (95)
47 (64) 99 (65) 21 (55) .07
17 (23) 34 (22) 6 (16) .8
7 (9) 5 (3) 7 (18) .0004
1 (1) 1 (0.66) 0 (0) .7
1 (1.3) 10 (5) 1 (3) .3
0 (0) 1 (0.7) 0 (0) .8
1 (1.3) 1 (0.7) 3 (8) .03
0 (0) 1 (0.7) 0 (0) .7
.0001
13 (14) 15 (8) 1 (2.5)
14 (15) 17 (9) 1 (2.5)
9 (9) 19 (10) 6 (15)
23 (24) 46 (25) 8 (20)
37 (38) 86 (47) 24 (60)
45 (47) 121 (66) 22 (55) .007
13 (14) 29 (16) 7 (18) .8
35 (36) 29 (16) 10 (25) .0002
3 (3) 4 (2) 1 (2.5) .9
62 (65) 110 (61) 24 (60) .5
9 (9) 15 (8) 3 (8) .7
7 (7) 17 (9) 5 (12) .8
6 (6) 16 (9) 2 (5) .2
1 (1) 5 (3) 0 (0) .6
46 (48) 103 (56) 24 (60) .0001
28 (29) 49 (27) 14 (35) .05
35 (36) 46 (25) 7 (18) .004
23 (24) 52 (28) 8 (20) .7
4 (4) 3 (2) 1 (2) .0001Any CABG 92 (47) 35 (36) 50 (27) 18 (45) .0007
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Electronic Appendix 1. continued
Characteristic
1, n  194 (38%),
No. (%)
2, n
Lesion
Right atrial lesion 9 (5)
NYHA, New York Heart Association; LAD, left anterior descending coronary
undergoing mitral valve surgery.
Electronic Appendix 2. Patient characteristics according
Characteristic 1
Demographic
Age (y) 68 12
Cardiac comorbidity
Duration of AF (mo)‡ 3, 24, 84
LV end-diastolic diameter (cm) 5.1 1.1
LV end-systolic diameter (cm) 3.7 1.4
Left atrial diameter (cm) 5 0.77
Fractional shortening 0.30 0.14 0
Ejection fraction (%) 54 22
Estimated wall stress 0.51 0.17 0
Noncardiac comorbidity
BUN (mg · dL1) 23  13
Bilirubin (mg · dL1)‡ 0.5, 0.8, 1.4 0
Hematocrit (%) 38 6
Intraoperative support
Aortic clamp time (min) 81 31
CPB time (min) 112 40
AF, Atrial fibrillation; LV, left ventricular; BUN, blood urea nitrogen; CPBLesion set
P value
 96 (19%),
No. (%)
3/4, n  183 (36%),
No. (%)
Other, n  40 (8%),
No. (%)
8 (8) 141 (77) 17 (42) .0001
artery; CABG, Coronary artery bypass grafting. *50%. †Percentage of patientsto lesion set: continuous variables*
Lesion set P
value†2 3/4 Other
67 12 67 11 64 13 .08
3, 31, 100 4, 36, 120 2, 13, 60 .006
5  0.95 5.1 0.87 5.4 0.88 .1
3.3 0.92 3.4 0.88 3.8 1.0 .09
5 0.78 5.3 1.0 5.5 0.88 .0005
.33 11 0.35 0.11 0.30 0.11 .008
59 17 62 15 56 16 .01
.51 0.21 0.47 0.13 0.45 0.13 .03
22 9 21 8 21 8 .9
.5, 0.8, 1.3 0.5, 0.8, 1.4 0.45, 1.0, 1.5 .6
38 6 38 5 38 5 .8
92 34 90 32 89 25 .006
115 40 113 37 116 33 .5
, cardiopulmonary bypass. *Mean  SD unless otherwise noted. †Wilcoxon
rank-sum nonparametric test. ‡Median, 15th, and 85th percentiles.
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. §Ln(relative wall thickness  5), logarithmic transformation.Electronic Appendix 3. Factors associated with lesion set
Factor
Lesion set 2 vs lesion set 1
Date of operation
Date of operation*
Fewer with RCA system disease
Higher ejection fraction†
Longer aortic clamp time
More with a mitral procedure
Lesion set 3 vs lesion set 1
Higher ejection fraction†
Fewer with paroxysmal AF
Fewer with RCA system disease
Longer aortic clamp time
Longer duration of AF‡
Fewer with heart failure
More with a mitral procedure
Fewer with diabetes
Lesion set 4 vs lesion set 1
Date of operation
Date of operation*
Fewer with paroxysmal AF
Higher ejection fraction†
Fewer with RCA system disease
Smaller septum§
Longer aortic clamp time
Fewer with aortic valve stenosis
More with a mitral procedure
RCA, Right coronary artery; AF, atrial fibrillation. *Ln(interval from date
logarithmic transformation. ‡Ln(duration of AF), logarithmic transformations
Estimate  SE P value
32  13 .01
390 155 .01
0.66 0.31 .03
1.6 0.48 .0006
0.015 0.005 .002
1.2 0.33 .0002
1.9 0.57 .0009
1.3  0.37 .0007
0.89 0.33 .006
0.016 0.0053 .004
0.31 0.11 .006
0.93 0.33 .004
1.5 0.37 .0001
1.2  0.51 .02
29 10 .002
333 116 .004
1.4  0.42 .0005
1.5 0.50 .003
1.5  0.36 .0001
2.9 1.0 .004
0.020 0.0057 .0003
1.3  0.45 .003
1.2 0.39 .003
of operation to 1/1/1991), logarithmic transformation. †Ln(ejection fraction),The Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 6 1329.e23
pass grafting. *50%. †Median, 15th, and 85th percentiles.Electronic Appendix 4. Patient characteristics within perm
Characteristic
1, n  101 (38%),
No. (%)
Demographic
Age (y), mean  SD 71 11
Cardiac comorbidity
Left main disease* 14 (15)
LAD disease* 48 (51)
Circumflex disease* 39 (41)
Right coronary disease* 45 (48)
Previous myocardial infarction 46 (46)
Mitral valve disease cause
Rheumatic 13 (13)
Degenerative 24 (24)
Mitral valve regurgitation grade
0 21 (21)
1 21 (21)
2 21 (21)
3 15 (15)
4 23 (23)
Ejection fraction (%), mean  SD 50 20
Left atrial diameter (cm)† 4.2, 5.2, 6.0
6 cm 13 (16)
Fractional shortening† 0.12, 0.26, 0.42
Procedure
Mitral valve repair 26 (26)
Mitral valve replacement 22 (22)
CABG 56 (55)
Lesion
Right atrial 8 (8)
LAD, Left anterior descending coronary artery; CABG, coronary artery byanent AF group
Lesion set
P value
2, n  45 (17%),
No. (%)
3/4, n  121 (45%),
No. (%)
70  9 69  10 .3
5 (11) 4 (3) .01
16 (37) 28 (24) .0002
14 (32) 26 (22) .01
15 (35) 26 (22) .0004
11 (24) 24 (20) .0001
12 (27) 25 (21) .1
22 (49) 66 (55) .0001
.004
9 (20) 11 (9)
6 (13) 12 (10)
5 (11) 16 (13)
8 (18) 27 (22)
17 (38) 55 (45)
58  14 62  16 .002
4.4, 5.0, 5.9 4.7, 5.5, 6.6 .01
4 (12) 31 (30) .03
0.22, 0.30, 0.45 0.23, 0.34, 0.47 .001
15 (33) 64 (53) .0001
19 (42) 37 (31) .04
20 (44) 34 (28) .0002
6 (13) 96 (79) .00011329.e24 The Journal of Thoracic and Cardiovascular Surgery ● June 2005
Electronic Appendix 5. Distribution of electrocardiographi
Time (mo) 0 1
Overall
No. of patients 513 313
No. of ECGs 3495 1070
Lesion set 1
No. of patients 194 115
No. of ECGs 1278 414
Lesion set 2
No. of patients 96 74
No. of ECGs 676 233
Lesion set 3
No. of patients 96 72
No. of ECGs 805 300
Lesion set 4
No. of patients 87 34
No. of ECGs 496 67
Other lesions
No. of patients 40 18
No. of ECGs 240 56
ECG, Electrocardiogram.c records over time
3 6 9 12
253 195 120 72
694 401 219 113
91 69 47 26
270 167 91 46
61 49 21 13
150 80 39 15
67 51 35 24
207 113 66 39
17 14 10 5
30 20 13 6
17 12 7 4
37 21 10 7The Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 6 1329.e25
Electronic Appendix 6. Variables used in the analyses
Preoperative
Demographic Age (y), sex, weight (k
Symptoms New York Heart Assoc
Left ventricular function Ejection fraction (%), e
shortening, mass (g)
volume (mL), end-dia
m2), posterior wall
Right ventricular function Estimated systolic pres
Atrial size LA diameter (cm), LA v
Mitral valve pathology Mitral regurgitation
Mitral valve disease cause Ischemic, rheumatic, d
Other valve pathology Aortic valve regurgitat
Cardiac comorbidity Complete heart block–
Noncardiac comorbidity Insulin-treated diabete
peripheral vascular
pulmonary disease,
nitrogen (mg · dL1)
Coronary anatomy Maximum % stenosis
right coronary artery
Experience Date of operation (yea
Atrial fibrillation types Permanent, persistent,
Thromboembolic events Transient ischemic att
Intraoperative
Procedure Internal thoracic arter
MV repair, MV repla
Lesion sets Lesion set 1, lesion se
connection between
veins, connection to
Source Cryothermy
Support Aortic clamp time (min
LA, Left atrium; MV, mitral valve.
Electronic Appendix Figure E1. Use of varg), height (cm), body surface area (m2), body mass index (kg · m2)
iation functional class (I-IV), emergency operation
nd-diastolic diameter (cm), end-systolic diameter (cm), fractional
, mass index (g · m2), end-diastolic volume (mL), end-systolic
stolic volume index (mL · m2), end-systolic volume index (mL ·
thickness (cm), estimated wall stress
sure
olume (mL), LA volume index (mL · m2)
egenerative
ion, tricuspid valve regurgitation
pacer, ventricular arrhythmia, number of previous cardiac operations
s, non–insulin-treated diabetes, treated diabetes, history of
disease, history of smoking, carotid disease, chronic obstructive
hypertension, renal disease, creatinine (mg · dL1), blood urea
, bilirubin (mg · dL1), hematocrit (%)
in: left main trunk, left anterior descending coronary artery system,
system, left circumflex coronary artery system
rs since January 1, 2001)
paroxysmal, duration of atrial fibrillation (mo)
ack, cerebrovascular accident
y graft used, coronary artery bypass grafting, tricuspid valve repair,
cement, MV bioprosthetic replacement, aortic valve replacement
t 2, lesion set 3, lesion set 4, connection to mitral annulus,
inferior pulmonary veins, connection between superior pulmonary
left atrial appendage, right atrial lesion
), cardiopulmonary bypass time (min)ious lesion sets (1-4) across the study period.1329.e26 The Journal of Thoracic and Cardiovascular Surgery ● June 2005
Electronic Appendix Figure E2. Prevalence of class I an
axis begins at 3 months, marking the first systematic
prevalences, but only approximate the data because o
represents the prevalence estimate from the logistic
limits.
Electronic Appendix Figure E3. Prevalence of warfari
Figure E2.d III antiarrhythmic agent use after ablation. The horizontal
follow-up of patients. Filled circles represent observed
f multiple follow-up inquiries per patient. The solid curve
mixed model, and dashed lines represent 68% confidencen use after ablation. Format is as for Electronic AppendixThe Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 6 1329.e27
Electronic Appendix Figure E4. Decomposition of temp
postoperative electrocardiograms, demonstrating 3 ph
phase, and a late rising phase.
Electronic Appendix Figure E5. Nomogram from the mu
left atrial diameters.oral pattern of atrial fibrillation (AF) after ablation, based on
ases of prevalence: an early peaking phase, a constantltivariable equation (Table 2) demonstrating the effect of 21329.e28 The Journal of Thoracic and Cardiovascular Surgery ● June 2005
Electronic Appendix Figure E6. Effect of (1) lesion set, (2) type of atrial fibrillation (AF), and (3) duration of AF (along
horizontal axis) on estimated 1-year freedom from ablation failure (vertical axis) based on multivariable analysis
(see Table 3). Dashed lines enclose 68% confidence limits.The Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 6 1329.e29
